378 related articles for article (PubMed ID: 9469355)
21. Neoadjuvant chemotherapy in malignant fibrous histiocytoma of bone and in osteosarcoma located in the extremities: analogies and differences between the two tumors.
Picci P; Bacci G; Ferrari S; Mercuri M
Ann Oncol; 1997 Nov; 8(11):1107-15. PubMed ID: 9426330
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: is a good response to preoperative treatment an indication to reduce postoperative chemotherapy?
Bacci G; Picci P; Gherlinzoni F; Van Horn JR; Orlandi M; Normand AR; Manfrini M; Pignatti G; Campanacci M
Chemioterapia; 1986 Apr; 5(2):140-3. PubMed ID: 3458546
[TBL] [Abstract][Full Text] [Related]
23. [Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients].
Bielack S; Kempf-Bielack B; Schwenzer D; Birkfellner T; Delling G; Ewerbeck V; Exner GU; Fuchs N; Göbel U; Graf N; Heise U; Helmke K; von Hochstetter AR; Jürgens H; Maas R; Münchow N; Salzer-Kuntschik M; Treuner J; Veltmann U; Werner M; Winkelmann W; Zoubek A; Kotz R
Klin Padiatr; 1999; 211(4):260-70. PubMed ID: 10472560
[TBL] [Abstract][Full Text] [Related]
24. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
Crews KR; Liu T; Rodriguez-Galindo C; Tan M; Meyer WH; Panetta JC; Link MP; Daw NC
Cancer; 2004 Apr; 100(8):1724-33. PubMed ID: 15073863
[TBL] [Abstract][Full Text] [Related]
25. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup.
Hauben EI; Weeden S; Pringle J; Van Marck EA; Hogendoorn PC
Eur J Cancer; 2002 Jun; 38(9):1218-25. PubMed ID: 12044509
[TBL] [Abstract][Full Text] [Related]
26. Serum methotrexate (MTX) concentrations and prognosis in patients with osteosarcoma of the extremities treated with a multidrug neoadjuvant regimen.
Ferrari S; Sassoli V; Orlandi M; Strazzari S; Puggioli C; Battistini A; Bacci G
J Chemother; 1993 Apr; 5(2):135-41. PubMed ID: 8515297
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant chemotherapy for radioinduced osteosarcoma of the extremity: The Rizzoli experience in 20 cases.
Bacci G; Longhi A; Forni C; Fabbri N; Briccoli A; Barbieri E; Mercuri M; Balladelli A; Ferrari S; Picci P
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):505-11. PubMed ID: 17118571
[TBL] [Abstract][Full Text] [Related]
28. Sex- and age-related chemotherapy toxicity in patients with non-metastatic osteosarcoma.
Ferrari S; Palmerini E; Staals E; Abate ME; Longhi A; Cesari M; Balladelli A; Pratelli L; Bacci G
J Chemother; 2009 Apr; 21(2):205-10. PubMed ID: 19423475
[TBL] [Abstract][Full Text] [Related]
29. Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter?
Yu W; Tang L; Lin F; Yao Y; Shen Z
Med Oncol; 2015 Jan; 32(1):307. PubMed ID: 25432694
[TBL] [Abstract][Full Text] [Related]
30. High-dose methotrexate (HD-MTX) used as an adjunct with other chemotherapeutics for the treatment of osteosarcoma.
Liu Y; Xu Y; Lin N; Jiang S; Wang Y; Ye Z
Cell Biochem Biophys; 2015 Mar; 71(2):1097-104. PubMed ID: 25417058
[TBL] [Abstract][Full Text] [Related]
31. A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity.
Bacci G; Ferrari S; Tienghi A; Bertoni F; Mercuri M; Longhi A; Fiorentini G; Forni C; Bacchini P; Rimondini S; De Giorgi U; Picci P
Eur J Surg Oncol; 2001 Feb; 27(1):98-104. PubMed ID: 11237499
[TBL] [Abstract][Full Text] [Related]
32. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol.
Meyers PA; Gorlick R; Heller G; Casper E; Lane J; Huvos AG; Healey JH
J Clin Oncol; 1998 Jul; 16(7):2452-8. PubMed ID: 9667263
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
[TBL] [Abstract][Full Text] [Related]
34. Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials.
Eselgrim M; Grunert H; Kühne T; Zoubek A; Kevric M; Bürger H; Jürgens H; Mayer-Steinacker R; Gosheger G; Bielack SS
Pediatr Blood Cancer; 2006 Jul; 47(1):42-50. PubMed ID: 16206218
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience.
Meyers PA; Heller G; Healey J; Huvos A; Lane J; Marcove R; Applewhite A; Vlamis V; Rosen G
J Clin Oncol; 1992 Jan; 10(1):5-15. PubMed ID: 1370176
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor.
Bacci G; Bertoni F; Longhi A; Ferrari S; Forni C; Biagini R; Bacchini P; Donati D; Manfrini M; Bernini G; Lari S
Cancer; 2003 Jun; 97(12):3068-75. PubMed ID: 12784343
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant chemotherapy for the treatment of osteosarcoma of the extremities: excellent response of the primary tumor to preoperative treatment with methotrexate, cisplatin, adriamycin, and ifosfamide. Preliminary results.
Bacci G; Picci P; Ferrari S; Sangiorgi L; Mercuri M; Bertoni F; Brach del Prever A; Tienghi A; Mancini A; Comandone A
Chir Organi Mov; 1995; 80(1):1-10. PubMed ID: 7641534
[TBL] [Abstract][Full Text] [Related]
38. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
[TBL] [Abstract][Full Text] [Related]
39. High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study.
Bacci G; Ferrari S; Longhi A; Picci P; Mercuri M; Alvegard TA; Saeter G; Donati D; Manfrini M; Lari S; Briccoli A; Forni C;
J Chemother; 2002 Apr; 14(2):198-206. PubMed ID: 12017378
[TBL] [Abstract][Full Text] [Related]
40. Intra-arterial versus intravenous cisplatinum (in addition to systemic Adriamycin and high dose methotrexate) in the neoadjuvant treatment of osteosarcoma of the extremities. results of a randomized study.
Bacci G; Ruggieri P; Picci P; Mercuri M; Ferraro A; Tella G; Ferrari S; Bertoni F; Comandone A
J Chemother; 1996 Feb; 8(1):70-81. PubMed ID: 8835114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
